Clinical trials: Varicella Zoster Vaccine
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00751348
- Testing
- PriorixTM, VarilrixTM, Priorix-Tetra®
- Where
- 13 sites in South Korea
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as…
- Trial name
- NCT03314103
- Testing
- One shot of the varicella-zoster virus vaccine
- Where
- 3 sites in China
- Volunteers
- 30,000 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Japanese Encephalitis, Chickenpox
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
The purpose of this study is to observe the occurrence of adverse events and seroconversion rate, geometric mean titres (GMTs) of live attenuated varicella vaccine，live attenuated JE vaccine and live attenuated varicella vaccine…
- Trial name
- NCT01815073
- Testing
- Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine, Live Attenuated Varicella Vaccine, live attenuated JE vaccine
- Where
- China
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- Changchun Keygen Biological Products Co., Ltd.
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
This is a randomized, observer blind and controlled study. Participants in low-dose and high-dose IM group will be randomized in a ratio of 2:1 to receive either the investigational product or the control.
- Trial name
- NCT05991427
- Testing
- Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV
- Where
- Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
Chickenpox
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax.
- Trial name
- NCT06693895
- Testing
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine
- Where
- 46 sites in United States, Bulgaria and 6 more
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety.
- Trial name
- NCT00568334
- Testing
- Varilrix (inactivated varicella vaccine)
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Zoster, Systemic Lupus Erythematosus
Immunogenicity, Reactogenicity of Shingrix in SLE
To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.
- Conditions
- Zoster, Systemic Lupus Erythematosus, Vaccine Reaction
- Trial name
- NCT06001606
- Testing
- Shingrix
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Seoul National University Hospital
Herpes Zoster
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another…
- Trial name
- NCT00231816
- Testing
- ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, ZOSTAVAX™ (Nonconcomitant)
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
Safety of a Second Dose of Biken's Varicella Vaccine
The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella…
- Trial name
- NCT00830648
- Testing
- Live Attenuated Varicella Virus Vaccine
- Where
- Argentina
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal…
- Trial name
- NCT07481604
- Testing
- Shingrix, CVI-VZV-001
- Where
- 7 sites in South Korea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Shingles
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
- Trial name
- NCT05554068
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Herpes Zoster
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete…
- Trial name
- NCT07293065
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- 4 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Hepatitis A, Measles
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly.
- Conditions
- Hepatitis A, Measles, Mumps, Rubella
- Trial name
- NCT00326183
- Testing
- VAQTA®, ProQuad
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella Zoster Infection
VZV Vaccine for Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is well-established therapy for patients with malignant hematological diseases. Varicella zoster virus (VZV) reactivation, clinically manifested as herpes zoster (HZ), is a major…
- Trial name
- VZIDST (NCT02329457)
- Testing
- Zostavax, Normal Saline
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Shingles, Zoster
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
- Trial name
- MSHINGVAX (NCT05596526)
- Testing
- recombinant zoster vaccine
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prof Patrice Lalive
HIV Infections, Chickenpox
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
The purpose of this study is to see if the varicella-zoster virus (VZV) vaccine will be safe and if it can help prevent shingles in HIV-infected children who have already had chickenpox. VZV is the virus that causes chickenpox.
- Trial name
- NCT00001125
- Testing
- Varicella Virus Vaccine (Live)
- Where
- 22 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting
The purpose of this study is to determine whether pharmacist-driven patient interventions can have an effect on the number of herpes zoster (Zostavax) vaccinations given in a community pharmacy setting.
- Trial name
- NCT00689013
- Testing
- Personalized letter, Flyer advertisement, Newspaper press release
- Where
- 3 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Varicella-zoster Virus
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the vaccine efficacy, safety and immunogenicity of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07817108
- Testing
- ABO1108
- Where
- 4 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.